Skip to search formSkip to main contentSkip to account menu

razaxaban

Known as: 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-(2-fluoro-4-((2'-dimethylaminomethyl)imidazol-1-yl)phenyl)-1H-pyrazole-5-carboxamide 
An orally active, 1,2-benzisoxazole-containing, inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Razaxaban forms… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

BMS 561389DPC 906

Broader (2)

IsoxazolesPyrazoles
razaxaban hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Warfarin and Newer Oral Anticoagulants : Long-term Prevention and Treatment of Arterial and VTE Evidence-based Synthesis Program EXECUTIVE SUMMARY BACKGROUND Thromboembolic diseases
Step Category Terms Result 1 Newer anticoagulants dabigatran OR desirudin OR ximelagatran OR edoxaban OR rivaroxaban OR apixaban… 
2011
2011
The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface
This study was designed to assess the effect of Factor Xa antagonists on thrombus formation at various axial positions on a… 
Review
2009
Review
2009
[Advances in antithrombotic treatment--antithrombotics with anti-Xa effect].
The use of anticoagulants in the prophylaxis and treatment of arterial and venous thrombosis has substantially expanded during… 
2006
2006
New anticoagulants and the management of their bleeding complications
SUMMARY Limitations of the currently available anticoagulants have fanned the continuing search for new anticoagulants with… 
Review
2005
Review
2005
Heterogeneity of synthetic factor Xa inhibitors.
Heparins and vitamin K antagonists are the landmarks of antithrombotic treatment. Both of them were discovered by serendipity… 
Review
2004
Review
2004
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
Traditional anticoagulants have drawbacks that make them complex to manage, limit their usefulness, and increase the possibility… 
Review
2003
Review
2003
Preparing for the New Anticoagulants
New anticoagulant agents with differing properties, risks, and potential economic consequences are becoming available. Two… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)